Placing of 50,000,000 New Ordinary Shares and Warrants

Placing of 50,000,000 New Ordinary Shares and Warrants
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.
Sub-contract approach for VISITECT® COVID-19 antigen test
Omega (ODX), the specialist medical diagnostics company, said that it has raised gross proceeds of £5.0 million. It also proposes to raise up to an additional £2.0 million.
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products announces that it has successfully CE marked its VISITECT®
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that Colin King, Chief Executive Officer, has notified the Board that
We were treated to a late RNS arrival yesterday from Omega (ODX), the specialist medical diagnostics company, as it noted concerns regarding the ability of certain lateral flow tests to
Halt the use of inaccurate Chinese lateral flow tests, with most already banned by the likes of the FDA.